financetom
Business
financetom
/
Business
/
MOVES-Goldman Sachs arm's global co-head and CIO of public investing to retire in 2026, memo says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MOVES-Goldman Sachs arm's global co-head and CIO of public investing to retire in 2026, memo says
Oct 15, 2025 2:58 PM

Oct 15 (Reuters) - Goldman Sachs Asset Management's

global co-head and chief investment officer of public investing,

Ashish Shah, will retire from the partnership next year,

according to a memo seen by Reuters on Wednesday.

Shah is set to assume the role of an advisory director, post

retirement, at the end of the first quarter of 2026, the memo

added.

After joining Goldman Sachs ( GS ) as a partner in 2018,

Shah served as global co-head and chief investment officer of

Fixed Income and Liquidity Solutions, where he was also a

portfolio manager for fixed income strategies.

Goldman Sachs ( GS ) has lost more than a dozen senior investment

bankers this year, a higher number than normal, after internal

shake-ups and a sluggish start to 2025 drove them to seek new

opportunities, Reuters reported on Monday, citing three sources

familiar with the situation.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints
Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints
May 31, 2024
09:23 AM EDT, 05/31/2024 (MT Newswires) -- Novartis ( NVS ) said Friday that the late-stage trial for its treatment for chronic myeloid leukemia, Scemblix, has met both of its primary endpoints. Scemblix demonstrated clinically significant efficacy that was better than select standard-of-care therapies of the same type, the drugmaker said. The drug's safety profile was consistent with previous studies...
Nvidia Isn't the Only Way to Play AI
Nvidia Isn't the Only Way to Play AI
May 31, 2024
09:23 AM EDT, 05/31/2024 (MT Newswires) -- Nvidia ( NVDA ) remains the dominant play in AI in the near-term, but there are other ways to play the AI story, according to The Compound and Friends podcast on Friday morning. Host Josh Brown says Nvidia ( NVDA ) will become larger than Apple ( AAPL ) on a market...
Johnson & Johnson Closes Acquisition of Shockwave Medical
Johnson & Johnson Closes Acquisition of Shockwave Medical
May 31, 2024
09:26 AM EDT, 05/31/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday that it has closed its acquisition of Shockwave Medical, which it said will operate as a business unit within Johnson & Johnson MedTech. The transaction is anticipated to dilute adjusted earnings per share by about $0.10 in 2024 and $0.17 in 2025 considering the impact...
Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer
Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer
May 31, 2024
On Thursday, Gilead Sciences Inc ( GILD ) announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC). The TROPiCS-04 study evaluated Trodelvy (sacituzumab govitecan-hziy; SG) vs. single-agent chemotherapy (treatment of physicians’ choice, TPC) in patients with mUC who have previously received platinum-containing chemotherapy and anti-PD-(L)1 therapy. Also Read: Gilead’s Aggressive Push Beyond...
Copyright 2023-2026 - www.financetom.com All Rights Reserved